论文部分内容阅读
目的评价沙利度胺联合复方斑蝥胶囊治疗进展期肝细胞癌的疗效及不良反应。方法沙利度胺(第1周100 mg/d,第2周起200 mg/d)联合复方斑蝥胶囊治疗(3粒/次,2次/d)直至疾病进展、死亡或出现不能耐受的副反应。结果 12例患者接受治疗,无完全缓解(CR)和部分缓解(PR)患者,疾病稳定(SD)5例(41.7%),疾病进展(PD)7例(58.3%),疾病控制率(DCR)41.7%;无进展生存(PFS)1.3～4.3个月,中位PFS为2个月;总生存(OS)2～6.7个月,中位OS为5.5个月。患者的KPS评分、睡眠、食欲、体质量、情绪等得到改善。最常见的不良反应为乏力和嗜睡。结论沙利度胺联合复方斑蝥胶囊治疗进展期肝细胞癌有一定疗效,并能改善患者的生活质量,且耐受性好、治疗费用低、用药方便,值得进一步扩大病例数开展临床研究。
Objective To evaluate the efficacy and adverse reactions of thalidomide combined with Canthaxanthirrhiza capsules in the treatment of advanced hepatocellular carcinoma. Methods Thalidomide (100 mg / d in the first week and 200 mg / d in the second week) was administered to the compound canthaxanthin capsules (3 capsules / time, twice daily) until disease progression, death or intolerance side effects. RESULTS: Twelve patients were treated with complete remission (CR) and partial remission (PR). Five patients (41.7%) had stable disease (SD), seven patients (58.3%) had disease progression (PD) ) 41.7%; progression-free survival (PFS) 1.3 to 4.3 months, median PFS was 2 months; overall OS was 2-6 months and median OS was 5.5 months. Patient KPS scores, sleep, appetite, body weight, mood, etc., were improved. The most common adverse reactions were fatigue and drowsiness. Conclusions Thalidomide combined with Canthaxanthirrhiza capsules has certain curative effect on advanced hepatocellular carcinoma and can improve the quality of life of patients with good tolerance, low cost of treatment and convenient medication. It is worth further expanding the number of cases to carry out clinical research.